Paula
Rodríguez Otero
Consultora Médica
Princess Margaret Cancer Centre
Toronto, CanadáPublications en collaboration avec des chercheurs de Princess Margaret Cancer Centre (4)
2021
-
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003
-
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Blood Cancer Journal, Vol. 11, Núm. 6
2020
-
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221